Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes

Clinical Cancer Research

Volumn 11, Issue 12, 2005, Pages 4545-4552

  Rodeberg, David A ^a,c   Nuss, Rebecca A ^a   Elsawa, Sherine F ^a   Celis, Esteban ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; HLA A2 ANTIGEN; METHIONYLISOLEUCYLALANYLVALYLPHENYLALANYLLEUCYLPROLYLISOLEUCYLVALINE; METHIONYLLEUCYLALANYLVALYLPHENYLALANYLLEUCYLPROLYLISOLEUCYLVALINE; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ALGORITHM; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; EWING SARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CACO-2 CELLS; CELL LINE; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 20444482839     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2235     Document Type: Article

References (29)

1. Rosenberg S. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
2. Pardoll DM. Therapeutic vaccination for cancer. Clin Immunol 2000;95:S44-62.
3. Renkvist N, Castelli C, Robbins P, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
4. Cells E, Tsai V, Crimi C, et al. Induction of amitumor cytotoxic t lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A 1994;91:2105-9.
5. Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/Neu tumor antigen. Cancer Res 2000;60:5228-36.
6. Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E. TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol 2001;166:7063-71.
7. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side chains. J Immunol 1994;152:163-75.
8. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stenanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-9.
9. Ruppert J, Sidney J, Cells E, Kubo R, Grey H, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74:929-37.
10. Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999;96:14523-8.
11. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 2001;61:5857-60.
12. Lu J, Celis E. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. Cancer Res 2000;60:5223-7.
13. Tsai V, Kawashima I, Keogh E, Daly K, Sette A, Celis E. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit Rev Immunol 1998;18:65-75.
14. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002;62:5807.
15. Smith JW II, Walker EB, Fox BA, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 2003; 21:1562-73.
16. Huarte E, Sarobe P, Lu J, et al. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clin Cancer Res 2002;8:2336-44.
17. Arndt CAS, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341:342-52.
18. Elwood JM, Koh HK. Etiology, epidemiology, risk factors, and public health issues of melanoma. Curr Opin Oncol 1994;6:179-87.
19. Komenaka I, Hoerig H, Kaufman H. Immunotherapy for melanoma. Clin Dermatol 2004;22:251-65.
20. Kobayashi H, Song Y, Hoon D, Appella E, Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 2001;61:4773-8.
21. Kobayashi H, Omiya R, Ruiz M, et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002;8:3219-25.
22. Schwartz RH. Acquisition of immunologic self-tolerance. Cell 1989;57:1073-81.
23. Sebzda E, Wallace VA, Mayer J, Yeung RSM, Mak TW, Ohashi PS. Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science 1994;263:1615-8.
24. Andersen MLM, Ruhwald M, Nissen MH, Buus S, Claesson MH. Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand J Immunol 2003;57:21-7.
25. Budd RC. Activation-induced cell death. Curr Opin Immunol 2001;13:356-62.
26. Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Nat Immunol 2003;4:410-5.
27. Ju S-T, Panka DJ, Cui H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
28. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002; 51:614-20.
29. Francini G, Scardino A, Kosmatopoulos K, et al. High-affinity HLAA (*) 02.01 Peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J Immunol 2002;169:4840-9.